Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis

Molecular Diagnosis and Therapy

Volumn 21, Issue 2, 2017, Pages 125-135

  Contro, Elena ^a   Bernabini, Dalila ^a   Farina, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; BIOLOGICAL MARKER;

CELL FREE SYSTEM; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; MEDLINE; META ANALYSIS; PREDICTION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SECOND TRIMESTER PREGNANCY; SIMULATION; SYSTEMATIC REVIEW; WEB OF SCIENCE; BODY MASS; CASE CONTROL STUDY; GENETICS; METABOLISM; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; DNA; FEMALE; FETUS; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84994779502     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-016-0245-9     Document Type: Review

References (35)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–99.
2. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143–8.
3. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10):1049–59.
4. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38(3 Pt 2):718–22.
5. Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH. Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47(5):554–9.
6. Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2015;15:191.
7. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–7.
8. Sekizawa A, Jimbo M, Saito H, Iwasaki M, Matsuoka R, Okai T, et al. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol. 2003;188(2):480–4.
9. Sifakis S, Koukou Z, Spandidos DA. Cell-free fetal DNA and pregnancy-related complications (review). Mol Med Rep. 2015;11(4):2367–72.
10. Hahn S, Rusterholz C, Hösli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta. 2011;32(Suppl):S17–20.
11. Martin A, Krishna I, Badell M, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat Diagn. 2014;34(7):685–91.
12. Lau TW, Leung TN, Chan LY, Lau TK, Chan KC, Tam WH, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002;48(12):2141e6.
13. Yu H, Shen Y, Ge Q, He Y, Qiao D, Ren M, et al. Quantification of maternal serum cell-free fetal DNA in early-onset preeclampsia. Int J Mol Sci. 2013;14(4):7571–82.
14. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol. 2009;201(5):472.e1–7.
15. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190(3):707–13.
16. Jakobsen TR, Clausen FB, Rode L, Dziegiel MH, Tabor A. Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA. Transfusion. 2013;53(9):1956–64.
17. Kim MJ, Kim SY, Park SY, Ahn HK, Chung JH, Ryu HM. Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications. Placenta. 2013;34(1):57–61.
18. Cotter AM, Martin CM, O’Leary JJ, Daly SF. Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. Am J Obstet Gynecol. 2004;191(2):515–20.
19. Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem. 2001;47(1):137–9.
20. Farina A, Sekizawa A, Sugito Y, Iwasaki M, Jimbo M, Saito H, et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn. 2004;24(2):83–6.
21. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002;21(1):77–83.
22. Stein W, Müller S, Gutensohn K, Emons G, Legler T. Cell-free fetal DNA and adverse outcome in low risk pregnancies. Eur J Obstet Gynecol Reprod Biol. 2013;166(1):10–3.
23. Cotter AM, Martin CM, O’Leary JJ, Daly SF. Increased fetal RhD gene in the maternal circulation in early pregnancy is associated with an increased risk of pre-eclampsia. BJOG. 2005;112(5):584–7.
24. Salvianti F, Inversetti A, Smid M, Valsecchi L, Candiani M, Pazzagli M, et al. Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia. Placenta. 2015;36(9):996–1001.
25. Crowley A, Martin C, Fitzpatrick P, Sheils O, O’Herlihy C, O’Leary JJ, et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn. 2007;27(2):174–9.
26. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357(9249):53–6.
27. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161(5):1200–4.
28. Illanes S, Parra M, Serra R, Pino K, Figueroa-Diesel H, Romero C, et al. Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. Prenat Diagn. 2009;29(12):1118–22.
29. Rolnik DL, O’Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2015;45(1):106–11.
30. Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks’ gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013;33(4):215–23.
31. Papantoniou N, Bagiokos V, Agiannitopoulos K, Kolialexi A, Destouni A, Tounta G, et al. RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenat Diagn. 2013;33(7):682–7.
32. Qi YH, Teng F, Zhou Q, Liu YX, Wu JF, Yu SS, et al. Unmethylated-maspin DNA in maternal plasma is associated with severe preeclampsia. Acta Obstet Gynecol Scand. 2015;94(9):983–8.
33. Tong YK, Ding C, Chiu RW, Gerovassili A, Chim SS, Leung TY, et al. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: theoretical and empirical considerations. Clin Chem. 2006;52(12):2194–202.
34. Daniels G, Finning K, Martin P, Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 2004;87(4):225–32.
35. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22.